Mechanisms of Disease: Astrocytes in neurodegenerative disease

Nature Clinical Practice Neurology

Volumn 2, Issue 12, 2006, Pages 679-689

  Maragakis, Nicholas J ^a   Rothstein, Jeffrey D ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; CEFTRIAXONE; CELL PROTEIN; CONNEXIN 43; COPPER ZINC SUPEROXIDE DISMUTASE; EPOXYICOSATRIENOIC ACID; GLIAL FIBRILLARY ACIDIC PROTEIN; GLUCOSE; GLUCOSE TRANSPORTER; GLUTAMATE TRANSPORTER; GLUTAMIC ACID; GLUTATHIONE; LEVODOPA; MEMANTINE; NITRIC OXIDE; PROSTAGLANDIN E2;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ASTROCYTE; CELL FUNCTION; CELL METABOLISM; CLINICAL FEATURE; CLINICAL TRIAL; DEGENERATIVE DISEASE; DISEASE ASSOCIATION; DRUG TARGETING; HUMAN; HUNTINGTON CHOREA; MEDICAL RESEARCH; NERVE CELL; NERVE DEGENERATION; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

ANIMALS; ASTROCYTES; DISEASE MODELS, ANIMAL; HUMANS; NEURODEGENERATIVE DISEASES;

EID: 33751237994     PISSN: 1745834X     EISSN: 17458358     Source Type: Journal    
DOI: 10.1038/ncpneuro0355     Document Type: Review

References (68)

1. Danbolt NC (2001) Glutamate uptake. Prog Neurobiol 65: 1-105
2. Kofuji P and Newman EA (2004) Potassium buffering in the central nervous system. Neuroscience 129: 1045-1056
3. Hirase H (2005) A multi-photon window onto neuronal-glial-vascular communication. Trends Neurosci 28: 217-219
4. Takano T et al. (2006) Astrocyte-mediated control of cerebral blood flow. Nat Neurosci 9: 260-267
5. Chaudhry FA et al. (1995) Glutamate transporters in glial plasma membranes: Highly differentiated localizations revealed by quantitative ultrastructural immunocytochemistry. Neuron 15:711-720
6. Lehre KP et al. (1995) Differential expression of two glial glutamate transporters in the rat brain: Quantitative and immunocytochemical observations. J Neurosci 15: 1835-1853
7. Milton ID et al. (1997) Expression of the glial glutamate transporter EAAT2 in the human CNS: An immunohistochemical study. Mol Brain Res 52:17-31
8. Rothstein JD et al. (1994) Localization of neuronal and glial glutamate transporters. Neuron 13:713-725
9. Rothstein JD et al. (1996) Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. Neuron 16:675-686
10. Tanaka K et al. (1997) Epilepsy and exacerbation of brain injury in mice lacking the glutamate transporter GLT-1. Science 276:1699-1702
11. Bezzi P et al. (2001) CXCR4-activated astrocyte glutamate release via TNFa: Amplification by microglia triggers neurotoxicity. Nat Neurosci 4:702-710
12. Haydon PG (2001) Glia: Listening and talking to the synapse. Nat Rev Neurosci 2: 185-193
13. Ye ZC et al. (2003) Functional hemichannels in astrocytes: A novel mechanism of glutamate release. J Neurosci 23: 3588-3596
14. Simard M and Nedergaard M (2004) The neurobiology of glia in the context of water and ion homeostasis. Neuroscience 129:877-896
15. Pekny M (2001) Astrocytic intermediate filaments: Lessons from GFAP and vimentin knock-out mice. Prog Brain Res 132:23-30
16. Eng LF et al. (1998) Astrocytes cultured from transgenic mice carrying the added human glial fibrillary acidic protein gene contain Rosenthal fibers. J Neurosci Res 53: 353-360
17. Wilhelmsson U et al. (2004) Absence of glial fibrillary acidic protein and vimentin prevents hypertrophy of astrocytic processes and improves post-traumatic regeneration. J Neurosci 24: 5016-5021
18. Tanaka K et al. (1997) Epilepsy and exacerbation of brain injury in mice lacking the glutamate transporter GLT-1. Science 276:1699-1702
19. Mitani A and Tanaka K (2003) Functional changes of glial glutamate transporter GLT-1 during ischemia: An in vivo study in the hippocampall CA1 of normal mice and mutant mice lacking GLT-1. J Neurosci 23: 7176-7182
20. Watanabe T et al. (1999) Amygdala-kindled and pentylenetetrazole-induced seizures in glutamate transporter GLAST-deficient mice. Brain Res 845:92-96
21. Mallolas J et al. (2006) A polymorphism in the EAAT2 promoter is associated with higher glutamate concentrations and higher frequency of progressing stroke. J Exp Med 203: 711-717
22. Sofroniew MV (2005) Reactive astrocytes in neural repair and protection. Neuroscientist 11: 400-407
23. Dermietzel R et al. (1991) Gap junctions between cultured astrocytes: immunocytochemical, molecular, and electrophysiological analysis. J Neurosci 11: 1421-1432
24. Reaume AG et al. (1995) Cardiac malformation in neonatal mice lacking connexin43. Science 267: 1831-1834
25. Siushansian R et al. (2001) Connexin43 null mutation increases infarct size after stroke. J Comp Neurol 440: 387-394
26. Patel SA and Maragakis NJ (2002) Amyotrophic lateral sclerosis: pathogenesis, differential diagnoses, and potential interventions. J Spinal Cord Med 25:262-273
27. Bristol LA and Rothstein JD (1996) Glutamate transporter gene expression in amyotrophic lateral sclerosis motor cortex. Ann Neurol 39: 676-679
28. Lin CL et al (1998) Aberrant RNA processing in a neurodegenerative disease: The cause for absent EAAT2, a glutamate transporter, in amyotrophic lateral sclerosis. Neuron 20: 589-602
29. Meyer T et al. (1999) The RNA of the glutamate transporter EAAT2 is variably spliced in amyotrophic lateral sclerosis and normal individuals. J Neurol Sci 170: 45-50
30. Flowers JM et al. (2001) Intron 7 retention and exon 9 skipping EAAT2 mRNA variants are not associated with amyotrophic lateral sclerosis. Ann Neurol 49: 643-649
31. Gurney ME et al. (1994) Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science 264: 1772-1775
32. Wong PC et al. (1995) An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron 14: 1105-1116
33. Bruijn LI et al. (1997) ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions. Neuron 18: 327-338
34. Howland DS et al. (2002) Focal loss of the glutamate transporter EAAT2 in atransgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS). Proc Natl Acad Sci USA 99: 1604-1609
35. Guo H et al. (2003) Increased expression of the glial glutamate transporter EAAT2 modulates excitotoxicity and delays the onset but not the outcome of ALS in mice. Hum Mol Genet 12:2519-2532
36. Clement AM et al. (2003) Wild-type nonneuronall cells extend survival of SOD1 mutant motor neurons in ALS mice. Science 302: 113-117
37. Miller TM et al. (2005) Virus-delivered small RNA silencing sustains strength in amyotrophic lateral sclerosis. Ann Neurol 57: 773-776
38. Ralph GS et al. (2005) Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model. Nat Med 11: 429-433
39. Selkoe DJ (2001) Alzheimer's disease: Genes, proteins, and therapy. Physiol Rev 81: 741-766
40. Wisniewski HM and Wegiel J (1991) Spatial relationships between astrocytes and classical plaque components. Neurobiol Aging 12: 593-600
41. DeWitt DA et al. (1998) Astrocytes regulate microglial phagocytosis of senile plaque cores of Alzheimer's disease. Exp Neurol 149:329-340
42. Nagele RG et al. (2004) Contribution of glial cells to the development of amyloid plaques in Alzheimer's disease. Neurobiol Aging 25: 663-674
43. Haughey NJ and Mattson MP (2003) Alzheimer's amyloid beta-peptide enhances ATP/gap junction-mediated calcium-wave propagation in astrocytes. Neuromolecular Med 3: 173-180
44. Johnston JM et al. (2006) Calcium oscillations in type-1 astrocytes, the effect of a presenilin 1 (PS1) mutation. Neurosci Lett 395: 159-164
45. Feany MB and Dickson DW (1995) Widespread cytoskeletal pathology characterizes corticobasal degeneration. Am J Pathol 146:1388-1396
46. Komori T (1999) Tau-positive glial inclusions in progressive supranuclear palsy, corticobasal degeneration and Pick's disease. Brain Pathol 9: 663-679
47. Forman MS et al. (2005) Transgenic mouse model of tau pathology in astrocytes leading to nervous system degeneration. J Neurosci 25: 3539-3550
48. Dabir DV et al. (2006) Impaired glutamate transport in a mouse model of tau pathology in astrocytes. J Neurosci 26: 644-654
49. Hersch SM et al. (2004) In Neurologic Principles and Practice, 503-526 (Ed Koller W) New York: McGraw-Hill
50. Singhrao SK et al. (1998) Huntingtin protein colocalizes with lesions of neurodegenerative diseases: An investigation in Huntington's, Alzheimer's, and Pick's diseases. Exp Neurol 150: 213-222
51. Arzberger T et al. (1997) Changes of NMDA receptor subunit (NR1, NR2B) and glutamate transporter (GLT1) mRNA expression in Huntington's disease - an in situ hybridization study. J Neuropathol Exp Neurol 56: 440-454
52. Rothstein JD et al. (1992) Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. N Engl J Med 326: 1464-1468
53. Vis JC et al. (1998) Connexin expression in Huntington's diseased human brain. Cell Biol Int 22: 837-847
54. Lievens JC et al. (2001) Impaired glutamate uptake in the R6 Huntington's disease transgenic mice. Neurobiol Dis 8: 807-821
55. Behrens PF et al. (2002) Impaired glutamate transport and glutamate-glutamine cycling: Downstream effects of the Huntington mutation. Brain 125: 1908-1922
56. Shin JY et al. (2005) Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity. J Cell Biol 171: 1001-1012
57. Nutt JG and Wooten GF (2005) Clinical practice: Diagnosis and initial management of Parkinson's disease. N Engl J Med 353: 1021-1027
58. Forno LS et al. (1992) Astrocytes and Parkinson's disease. Prog Brain Res 94: 429-436
59. Damier P et al. (1993) Glutathione peroxidase, glial cells and Parkinson's disease. Neuroscience 52: 1-6
60. Wakabayashi K et al. (2000) NACP/α-synucleinpositive filamentous inclusions in astrocytes and oligodendrocytes of Parkinson's disease brains. Acta Neuropathol (Berl) 99: 14-20
61. Teismann P and Schutz JB (2004) Cellular pathology of Parkinson's disease: Astrocytes, microglia and inflammation. Cell Tissue Res 318: 149-161
62. Saura J et al. (2003) Intranigral infusion of interleukin-1 beta activates astrocytes and protects from subsequent 6-hydroxydopamine neurotoxicity. J Neurochem 85: 651-661
63. Heales SJ et al. (2004) Neurodegeneration or neuroprotection: The pivotal role of astrocytes. Neurochem Res 29: 513-519
64. Maragakis NJ and Rothstein JD (2004) Glutamate transporters: Animal models to neurologic disease. Neurobiol Dis 15: 461-473
65. Brenner M et al. (2001) Mutations in GFAP, encoding glial fibrillary acidic protein, are associated with Alexander disease. Nat Genet 27: 117-120
66. Li R et al. (2005) Glial fibrillary acidic protein mutations in infantile, juvenile, and adult forms of Alexander disease. Ann Neurol 57: 310-326
67. Rothstein JD et al. (2005) Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 433: 73-77
68. Watanabe M et al. (2001) Histological evidence of protein aggregation in mutant SOD1 transgenic mice and in amyotrophic lateral sclerosis neural tissues. Neurobiol Dis 8: 933-941